271 related articles for article (PubMed ID: 35014202)
1. C/EBPβ promotes the expression of atrophy-inducing factors by tumours and is a central regulator of cancer cachexia.
AlSudais H; Rajgara R; Saleh A; Wiper-Bergeron N
J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):743-757. PubMed ID: 35014202
[TBL] [Abstract][Full Text] [Related]
2. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
3. Expression of CCAAT/Enhancer Binding Protein Beta in Muscle Satellite Cells Inhibits Myogenesis in Cancer Cachexia.
Marchildon F; Lamarche É; Lala-Tabbert N; St-Louis C; Wiper-Bergeron N
PLoS One; 2015; 10(12):e0145583. PubMed ID: 26709824
[TBL] [Abstract][Full Text] [Related]
4. Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway.
Chen L; Yang Q; Zhang H; Wan L; Xin B; Cao Y; Zhang J; Guo C
J Ethnopharmacol; 2020 Oct; 260():113066. PubMed ID: 32505837
[TBL] [Abstract][Full Text] [Related]
5. Group I Paks support muscle regeneration and counteract cancer-associated muscle atrophy.
Cerquone Perpetuini A; Re Cecconi AD; Chiappa M; Martinelli GB; Fuoco C; Desiderio G; Castagnoli L; Gargioli C; Piccirillo R; Cesareni G
J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):727-746. PubMed ID: 29781585
[TBL] [Abstract][Full Text] [Related]
6. C/EBPβ mediates tumour-induced ubiquitin ligase atrogin1/MAFbx upregulation and muscle wasting.
Zhang G; Jin B; Li YP
EMBO J; 2011 Aug; 30(20):4323-35. PubMed ID: 21847090
[TBL] [Abstract][Full Text] [Related]
7. REDD1 deletion attenuates cancer cachexia in mice.
Hain BA; Xu H; VanCleave AM; Gordon BS; Kimball SR; Waning DL
J Appl Physiol (1985); 2021 Dec; 131(6):1718-1730. PubMed ID: 34672766
[TBL] [Abstract][Full Text] [Related]
8. From quiescence to repair: C/EBPβ as a regulator of muscle stem cell function in health and disease.
AlSudais H; Wiper-Bergeron N
FEBS J; 2022 Nov; 289(21):6518-6530. PubMed ID: 34854237
[TBL] [Abstract][Full Text] [Related]
9. CCAAT/Enhancer Binding Protein β inhibits myogenic differentiation via ID3.
AlSudais H; Lala-Tabbert N; Wiper-Bergeron N
Sci Rep; 2018 Nov; 8(1):16613. PubMed ID: 30413755
[TBL] [Abstract][Full Text] [Related]
10. Patient-Derived Pancreatic Cancer Cells Induce C2C12 Myotube Atrophy by Releasing Hsp70 and Hsp90.
Wu HY; Trevino JG; Fang BL; Riner AN; Vudatha V; Zhang GH; Li YP
Cells; 2022 Sep; 11(17):. PubMed ID: 36078164
[TBL] [Abstract][Full Text] [Related]
11. Cancer-Induced Muscle Wasting Requires p38β MAPK Activation of p300.
Sin TK; Zhang G; Zhang Z; Zhu JZ; Zuo Y; Frost JA; Li M; Li YP
Cancer Res; 2021 Feb; 81(4):885-897. PubMed ID: 33355181
[TBL] [Abstract][Full Text] [Related]
12. Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia.
Pin F; Barreto R; Kitase Y; Mitra S; Erne CE; Novinger LJ; Zimmers TA; Couch ME; Bonewald LF; Bonetto A
J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):685-700. PubMed ID: 30009406
[TBL] [Abstract][Full Text] [Related]
13. Cathepsin K activity controls cachexia-induced muscle atrophy via the modulation of IRS1 ubiquitination.
Meng X; Huang Z; Inoue A; Wang H; Wan Y; Yue X; Xu S; Jin X; Shi GP; Kuzuya M; Cheng XW
J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1197-1209. PubMed ID: 35098692
[TBL] [Abstract][Full Text] [Related]
14. FoxP1 is a transcriptional repressor associated with cancer cachexia that induces skeletal muscle wasting and weakness.
Neyroud D; Nosacka RL; Callaway CS; Trevino JG; Hu H; Judge SM; Judge AR
J Cachexia Sarcopenia Muscle; 2021 Apr; 12(2):421-442. PubMed ID: 33527776
[TBL] [Abstract][Full Text] [Related]
15. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy.
Zhong X; Pons M; Poirier C; Jiang Y; Liu J; Sandusky GE; Shahda S; Nakeeb A; Schmidt CM; House MG; Ceppa EP; Zyromski NJ; Liu Y; Jiang G; Couch ME; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1083-1101. PubMed ID: 31286691
[TBL] [Abstract][Full Text] [Related]
16. IFIT2-depleted metastatic oral squamous cell carcinoma cells induce muscle atrophy and cancer cachexia in mice.
Lai KC; Hong ZX; Hsieh JG; Lee HJ; Yang MH; Hsieh CH; Yang CH; Chen YR
J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1314-1328. PubMed ID: 35170238
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour-bearing mice.
Brown JL; Rosa-Caldwell ME; Lee DE; Blackwell TA; Brown LA; Perry RA; Haynie WS; Hardee JP; Carson JA; Wiggs MP; Washington TA; Greene NP
J Cachexia Sarcopenia Muscle; 2017 Dec; 8(6):926-938. PubMed ID: 28845591
[TBL] [Abstract][Full Text] [Related]
18. IL-17A contributes to skeletal muscle atrophy in lung cancer-induced cachexia via JAK2/STAT3 pathway.
Ying L; Yao Y; Lv H; Lu G; Zhang Q; Yang Y; Zhou J
Am J Physiol Cell Physiol; 2022 May; 322(5):C814-C824. PubMed ID: 35319902
[TBL] [Abstract][Full Text] [Related]
19. Targeting RAGE prevents muscle wasting and prolongs survival in cancer cachexia.
Chiappalupi S; Sorci G; Vukasinovic A; Salvadori L; Sagheddu R; Coletti D; Renga G; Romani L; Donato R; Riuzzi F
J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):929-946. PubMed ID: 32159297
[TBL] [Abstract][Full Text] [Related]
20. Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice.
Kandarian SC; Nosacka RL; Delitto AE; Judge AR; Judge SM; Ganey JD; Moreira JD; Jackman RW
J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1109-1120. PubMed ID: 30270531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
